The International Generic and Biosimilar Medicines Association’s (IGBA) CEO Advisory Committee held an exchange with Mr. Daren Tang, Director General of the World Intellectual Property Organization (WIPO). This was the first opportunity for Mr. Tang to engage in a direct dialogue with IGBA CEO Advisory Committee Members.
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that ANAFAM has been accepted and welcomed as a new IGBA Associate Member.
On 20 July 2023, the International Coalition of Medicines Regulatory Authorities (ICMRA) is hosting a virtual workshop on the development of a global Pharmaceutical Quality Knowledge Management System (PQ KMS), which aims to facilitate the exchange of knowledge related to pharmaceutical quality amongst national regulatory authorities worldwide.
- IGBA Welcomes ICH New Topic for Harmonisation: “Bioequivalence for Modified-Release Products” (June 2023)
- IGBA CEO Advisory Committee Vienna Statement - Four Keys to More Predictable Supply Chains (June 2023)
- IGBA detailed comments and proposals on the Pandemic Accord (Zero Draft - May 2023)
- IGBA Perspectives on Pandemic Accord (Zero Draft – April 2023)
